Shanghai Hongmai Medical Technology Co., Ltd. announced that it will raise CNY 45 million in an equity round of funding on December 14, 2022. The transaction includes participation from new investor Shanghai Xiying Enterprise Consulting Partnership (Limited Partnership) for CNY 35 million and returning investor Shanghai MicroPort Endovascular MedTech Co., Ltd for CNY 10 million. After the completion of this capital increase, Shanghai MicroPort Endovascular MedTech Co., Ltd will hold 65% of the company, Shanghai Xiying Enterprise Consulting Partnership (Limited Partnership) will hold 35% of company, and the registered capital of the company will increase from CNY 55 million to CNY 100 million.

The transaction was approved by the board of directors in its thirteenth meeting of the second session, which was delivered to all directors on December 9, 2022. The round is raised at a pre-money valuation of CNY 55 million.